195
Views
11
CrossRef citations to date
0
Altmetric
Perspective

Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?

&

References

  • Mascarenhas J, Mesa R, Prchal J, et al. Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials. Haematologica 2014;99(6):945-9
  • Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European Leukemia Net. J Clin Oncol 2011;29(6):761-70
  • Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88(6):507-16
  • Linkesch W, Gisslinger H, Ludwig H, et al. Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses [in German]. Acta Med Austriaca 1985;12:123-7
  • Silver RT. Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet 1988;2(8607):403
  • Silver RT. Interferon alfa: effects of long-term treatment for polycythemia vera. Semin Hematol 1997;34(1):40-50
  • Gilbert HS. Long term treatment of myeloproliferative disease with interferon alpha-2b: Feasibility and efficacy. Cancer 1998;83:1205-13
  • Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006;107:451-8
  • Samuelsson J, Hasselbalch H, Bruserud O, et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: Feasibility, clinical and biologic effects, and impact on quality of life. Cancer 2006;106:2397-405
  • Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006;108(6):2037-40
  • Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: Final results of a phase 2 study. Cancer 2007;110:2012-18
  • Quintas- Cardama A, Kantarjian H, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009;27:5418-24
  • Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112:3065-72
  • Gowin K, Thapaliya P, Samuelson J, et al. Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 2012;97(10):1570-3
  • Larsen TS, Iversen KF, Hansen E, et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res 2013;37(9):1041-5
  • Silver RT, Vandris K, Goldman JJ. Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report. Blood 2011;117(24):6669-72
  • Ianotto JC, Boyer-Perrard F, Gyan E, et al. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol 2013(6):783-91
  • Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood 2013;122(6):893-901
  • Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-ablnegative myeloproliferative neoplasms. Leukemia 2008;22:1990-8
  • Hasselbalch HC, Larsen TS, Riley CH, et al. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms: Status and perspectives. Curr Drug Targets 2011;12:392-419
  • Hasselbalch HC. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol 2011;4(6):637-55
  • Hasselbalch HC, Kiladjian JJ, Silver RT. Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. J Clin Oncol 2011;29(18):e564-5
  • Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011;117(18):4706-15
  • Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol 2013;6(1):49-58
  • Hasselbalch HC. Myelofibrosis with myeloid metaplasia: The advanced phase of an untreated disseminated hematological cancer—Time to change our therapeutic attitude with early upfront treatment? Leuk Res 2009;33:11-18
  • Larsen TS, Bjerrum OW, Pallisgaard N, et al. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. Ann Hematol 2008;87(10):847-50
  • Larsen TS, Møller MB, de Stricker K, et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera: A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 2009;14:331-4
  • Cassinat B, Verger E, Kiladjian JJ. Interferon alfa therapy in CALR-mutated essential thrombocythemia. N Engl J Med 2014;371(2):188-9
  • Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.Blood. 2014;123(14):2220-8
  • Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 2011;96(2):315-18
  • Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011;29(10):1356-63
  • Vaidya R, Gangat N, Jimma T, et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol 2012;87(11):1003-5
  • Skov V, Thomassen M, Riley CH, et al. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Exp Hematol 2012;40(9):771-80
  • Skov V, Larsen TS, Thomassen M, et al. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res 2012;36(11):1387-92
  • Barbui T, Carobbio A, Finazzi G, et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia 2013;27(10):2084-6
  • Hasselbalch HC. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev 2013;24(2):133-45
  • Bjørn ME, Andersen CL, Jensen MK, et al. Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state. Eur J Haematol 2014;93(3):224-8
  • Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 2012;119(14):3219-25
  • Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia,polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res 2013;37(2):214-20
  • Hasselbalch HC. Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Expert Rev Hematol 2014;7(2):203-16
  • Enblom A, Lindskog E Hasselbalch HC, et al. High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. Eur J Intern Med 2015. [Epub ahead of print]
  • Marty C, Lacout C, Droin N, et al. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia 2013;27(11):2187-95
  • Vannucchi AM. JAK2 mutation and thrombosis in the myeloproliferative neoplasms Curr Hematol Malig Rep. 2010;5(1):22-8
  • Hasselbalch HC, Thomassen M, Riley CH, et al. Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression. PLoS One 2014;9(11):e112786
  • Nielsen C, Birgens HS, Nordestgaard BG, et al. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population. Br J Haematol 2013;160(1):70-9
  • Nakatake M, Monte-Mor B, Debili N, et al. JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene 2012;31(10):1323-33
  • Plo I, Nakatake M, Malivert L, et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008;112(4):1402-12
  • Nielsen C, Bojesen SE, Nordestgaard BG, et al. JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate. Haematologica 2014;99(9):1448-55
  • Kiladjian JJ, Massé A, Cassinat B, et al. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia 2010;24(8):1519-23
  • Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood 2013;122(6):893-901
  • Chen E, Beer PA, Godfrey AL, et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell 2010;18(5):524-35
  • Fretham SJ, Carlson ES, Georgieff MK. The role of iron in learning and memory. Adv Nutr 2011;2(2):112-21
  • Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: Systematic review and meta-analysis. Eur J Heart Fail 2012;14(4):423-9
  • Balci K, Utku U, Asil T, et al. Deep cerebral vein thrombosis associated with iron deficiency anaemia in adults. J Clin Neurosci 2007;14(2):181-4
  • Kiladjian JJ, Rain JD, Bernard JF, et al. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006;32:417-21
  • Kiladjian JJ, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011;29(29):3907-13
  • Spivak JL, Hasselbalch H. Hydroxycarbamide: a user’s guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther 2011;11(3):403-14
  • Latagliata R, Spadea A, Cedrone M, et al. Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug. Cancer 2012;118(2):404-9
  • Estève E, Georgescu V, Heitzmann P, et al. Multiple skin and mouth squamous cell carcinomas related to long-term treatment with hydroxyurea. Ann Dermatol Venereol 2001;128(8-9):919-21
  • BC Cancer Agency Cancer Drug Manual© Developed: Hydroxyurea. September 1994 Revised: December 2006, 1 October 2013
  • Kissova J, Ovesna P, Penka M, et al. Second malignancies in Philadelphia-negative myeloproliferative neoplasms-single-center experience. Anticancer Res 2014;34(5):2489-96
  • Frederiksen H, Farkas DK, Christiansen CF, et al. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 2011;118:6515-20
  • Pettersson H, Knutsen H, Holmberg E, et al. Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis. Eur J Haematol 2014; Epub ahead of print
  • Hasselbalch HC. Editorial: Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis. Eur J Haematol 2014; Epub ahead of print
  • Riley CH, Jensen MK, Brimnes MK, et al. Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α. Blood 2011;118(8):2170-3
  • Skov V, Riley CH, Thomassen M, et al. Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leuk Lymphoma 2013;54(10):2269-73
  • Riley CH, Hansen M, Brimnes MK, et al. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-alpha. Eur J Haematol 2015;94(3):227-34
  • Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105(7):2664-70
  • Björkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011;29(17):2410-15
  • Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013;27(9):1874-81
  • Bjørn ME, de Stricker K, Kjær L, et al. Combination therapy with interferon and JAK1-2 inhibitor is feasible. proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera. Leuk Res Reports 2014;3(2):73-5
  • Sackett DL, Rosenberg WM, Gray JA, et al. Editorials Evidence based medicine: what it is and what it isn’t. Br Med J 1996;312:71-2
  • Day S. Evidence-based medicine and rare diseases. Chapter 3 in. Posada de la Paz M, Groft SC, Editors. Rare diseases epidemiology. Advances in experimental medicine and biology 2010. p. 41-53
  • Huang BT, Zeng QC, Zhao WH, et al. Interferon-alpha2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. Leuk Res 2014;38(10):1177-83
  • Simon R, Rothenberg ML, Sommer J, et al. The role of non-randomized trials in the evaluation of oncology drugs. Clin Pharmacol Ther 2015;97(5):502-7
  • Hasselbalch HC. The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis? Leuk Res 2014;38(10):1230-6
  • Randomized trial of pegylated interferon alfa-2a versus hydroxyurea in polycythemia vera (PV) and essential thrombocythemia (ET). Available from: https://clinicaltrials.gov/ct2/show/NCT01259856
  • Pegylated interferon alpha-2b versus hydroxyurea in polycythemia vera (PROUD-PV). Available from: https://clinicaltrials.gov/ct2/show/NCT01949805
  • A Danish study of low-dose interferon-alfa versus hydroxyurea in the treatment of Philadelphia chromosome negative (Ph-) chronic myeloproliferative neoplasms. A national randomized prospective study with focus upon efficacy, toxicity and quality of life. Available from: http://clinicaltrials.gov/ct2/show/NCT01387763
  • Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015;372(5):426-35

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.